WHO ICTRP trial
Study to Evaluate the Safety and Efficacy of a Combination of Nitazoxanide and…
CTRI/2020/06/025849 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/06/025849 |
|---|---|
| Public title | Study to Evaluate the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in COVID-19 Patients |
| Scientific title | A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients |
| Primary sponsor | Dr Reddys Laboratories Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere |
| Interventions | Intervention1: Hydroxychloroquine: 600 mg QD (on Days 1 and 2) followed by 200 mg BID (on Days 3 to 14) Intervention2: Nitazoxanide and Hydroxychloroquine: Nitazoxanide: 1000 mg QD (on Days 1 and 2) followed by 500 mg BID (on Days 3 to 14)… |
| Registration date | Dec 6, 2020 |
| Target size | 158 |
| Secondary IDs | CVD-19-CD-001; Version 4.0; 14 July 2020 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: